Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
Immune checkpoint inhibitors are a new treatment option in metastatic urothelial cancer on the basis of available phase 2 and 3 trials. Predictive biomarkers are needed. These should go beyond PD-L1 expression, which is showing inconsistent results across trials.